For patients with advanced or metastatic NSCLC harboring HER-2 mutation, chemotherapy should be employed, either in combination or without immunotherapy,300,332 however, single-agent ICIs are generally not recommended. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.